Solid Tumours

Personalised Healthcare

WAYFIND-R: A Global Initiative Empowering Research in Precision Oncology

WAYFIND-R is a multi-country, multi-site, prospective cancer registry that collects real-world data from adult patients diagnosed with a solid tumour and profiled with next-generation sequencing. The poster outlines WAYFIND-R objectives and provides an overview of current registry data, as well as detailing how the WAYFIND-R® Data Sharing and Collaboration Platform can support researchers with generating evidence that can be used to advance precision oncology.

Personalised Healthcare

Next-generation sequencing (NGS) in routine care: Medical practice in 24 countries from the pan-cancer WAYFIND-R registry

The poster describes NGS in routine care in most common cancer types using the global WAYFIND-R registry database.

Phase I Study of SOF10 Plus Atezolizumab in Patients with Advanced/Recurrent Solid Tumours

This was a Phase I, multicentre, open-label, dose-escalation study (jRCT2031200407) to evaluate the safety, tolerability, pharmacokinetics (PK) and anti-tumour activity of SOF10 (100-1800 mg) + atezolizumab (1200 mg) administered intravenously in patients with advanced/recurrent solid tumours.

Personalised Healthcare

Empowering research with seamless data flow and research-ready, anonymised data in OMOP CDM: Learnings from the design of WAYFIND-R, a global precision oncology registry and research platform

WAYFIND-R: A Global, Real-World Precision Oncology Registry – Socioeconomic Features

WAYFIND-R is a global, multicentre, prospective pan-cancer registry collecting long-term data from patients diagnosed with a solid tumour profiled with next-generation sequencing (NGS).

A Phase I study of a tumor-targeted fibroblast activation protein (FAP)-CD40 agonist (RO7300490) in patients with advanced solid tumors

Fibroblast activation protein (FAP)-CD40 is a FAP-targeted CD40 agonist bispecific antibody that was developed to overcome the systemic toxicities and narrow therapeutic index of conventional anti-CD40 therapies. This Phase I study evaluated the safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of FAP-CD40 in adults with solid tumors.

External site

Solid Tumours

Ask a question or share feedback